Increasing incidence of ductal carcinoma in situ (DCIS) confronts patients and clinicians with optimal treatment decisions. This multidisciplinary study investigates therapeutic modalities of DCIS in daily practice and provides recommendations on how to increase quality of care
Management of low-risk ductal carcinoma in situ (DCIS) is controversial, with clinical trials curren...
Ductal carcinoma in situ (DCIS) is a noninvasive breast cancer. While debate persists about its most...
Ductal carcinoma in situ (DCIS) of the breast is diagnosed more and more often in the Netherlands as...
Background: Increasing incidence of ductal carcinoma in situ (DCIS) confronts patients and clinician...
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. It accounts f...
Ductal carcinoma in situ (DCIS) now represents 20–25% of all ‘breast cancers’ consequent upon detect...
Ductal carcinoma in situ (DCIS) is noninvasive breast cancer that encompasses a wide spectrum of dis...
AIM: The ductal carcinoma in situ (DCIS) is a more and more frequent neoplasia, representing over 2...
Aim: The ductal carcinoma in situ is a malignant proliferation of mammary ductal epithelial cells wi...
INTRODUCTION: Selecting the appropriate treatment strategy for the individual patient with DCIS repr...
Several dilemmas exist when treating a patient with ductal carcinoma in situ (DCIS): the high rate o...
Ductal carcinoma in situ (DCIS) is a proliferation of presumably malignant epithelial cells within t...
The incidence of ductal carcinoma in situ (DCIS), a nonin-vasive form of breast cancer, has increase...
Introduction Ductal carcinoma in situ (DCIS) – heterogeneous group of diseases. Numbers of DCIS afte...
Introduction. This article reviews current management strategies for DCIS in the context of recent r...
Management of low-risk ductal carcinoma in situ (DCIS) is controversial, with clinical trials curren...
Ductal carcinoma in situ (DCIS) is a noninvasive breast cancer. While debate persists about its most...
Ductal carcinoma in situ (DCIS) of the breast is diagnosed more and more often in the Netherlands as...
Background: Increasing incidence of ductal carcinoma in situ (DCIS) confronts patients and clinician...
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. It accounts f...
Ductal carcinoma in situ (DCIS) now represents 20–25% of all ‘breast cancers’ consequent upon detect...
Ductal carcinoma in situ (DCIS) is noninvasive breast cancer that encompasses a wide spectrum of dis...
AIM: The ductal carcinoma in situ (DCIS) is a more and more frequent neoplasia, representing over 2...
Aim: The ductal carcinoma in situ is a malignant proliferation of mammary ductal epithelial cells wi...
INTRODUCTION: Selecting the appropriate treatment strategy for the individual patient with DCIS repr...
Several dilemmas exist when treating a patient with ductal carcinoma in situ (DCIS): the high rate o...
Ductal carcinoma in situ (DCIS) is a proliferation of presumably malignant epithelial cells within t...
The incidence of ductal carcinoma in situ (DCIS), a nonin-vasive form of breast cancer, has increase...
Introduction Ductal carcinoma in situ (DCIS) – heterogeneous group of diseases. Numbers of DCIS afte...
Introduction. This article reviews current management strategies for DCIS in the context of recent r...
Management of low-risk ductal carcinoma in situ (DCIS) is controversial, with clinical trials curren...
Ductal carcinoma in situ (DCIS) is a noninvasive breast cancer. While debate persists about its most...
Ductal carcinoma in situ (DCIS) of the breast is diagnosed more and more often in the Netherlands as...